MedTrace Logo

Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)

NCT00132639 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of the preoperative docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal preoperative therapy for phase III trials.

Conditions

  • Pulmonary Neoplasms

Interventions

DRUG

Preoperative docetaxel-cisplatin combination chemotherapy

Preoperative docetaxel-cisplatin combination chemotherapy

DRUG

Preoperative docetaxel monotherapy

Preoperative docetaxel monotherapy

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Haruhiko Fukuda

    lead OTHER

Principal Investigators

  • Harubumi Kato, MD, PhD · Tokyo Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132639 on ClinicalTrials.gov